Literature DB >> 11519726

Psychosine is as potent an inducer of cell death as C6-ceramide in cultured fibroblasts and in MOCH-1 cells.

J Tohyama1, J Matsuda, K Suzuki.   

Abstract

Cytotoxic capacity of psychosine (galactosylsphingosine) was evaluated in comparison with C6-ceramide in cultured fibroblasts and the glia-derived MOCH-1 cells that have characteristics of myelinating cells (1). Psychosine caused cytotoxic cell death and DNA fragmentation at concentrations similar to C6-ceramide and MOCH-1 cells were substantially more sensitive to their cytotoxic effects than fibroblasts. In this system, pretreatment with GM1-ganglioside failed to protect the cells from the deleterious effects of these compounds. These findings are consistent with the hypothesis that psychosine is the cytotoxic metabolite that causes apoptotic death of the oligodendrocyte in globoid cell leukodystrophy (Krabbe disease). They further suggest that the protective capacity of GM1-ganglioside is unlikely to be the explanation for the paradoxical improvement of the phenotype of globoid cell leukodystrophy in the mouse simultaneously deficient in two lysosomal beta-galactosidases, galactosylceramidase and GM1-ganglioside beta-galactosidase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11519726     DOI: 10.1023/a:1010991420942

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  20 in total

Review 1.  Physiology and pathophysiology of sphingolipid metabolism and signaling.

Authors:  A Huwiler; T Kolter; J Pfeilschifter; K Sandhoff
Journal:  Biochim Biophys Acta       Date:  2000-05-31

2.  PHYSIOLOGICAL ACTIVITY OF PSYCHOSINE.

Authors:  T TAKETOMI; K NISHIMURA
Journal:  Jpn J Exp Med       Date:  1964-10

3.  Ceramide accumulation is associated with increased apoptotic cell death in cultured fibroblasts of sphingolipid activator protein-deficient mouse but not in fibroblasts of patients with Farber disease.

Authors:  J Tohyama; Y Oya; T Ezoe; M T Vanier; H Nakayasu; N Fujita; K Suzuki
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

Review 4.  Sphingosine 1-phosphate: a prototype of a new class of second messengers.

Authors:  S Spiegel
Journal:  J Leukoc Biol       Date:  1999-03       Impact factor: 4.962

5.  Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase.

Authors:  C N Hahn; M del Pilar Martin; M Schröder; M T Vanier; Y Hara; K Suzuki; K Suzuki; A d'Azzo
Journal:  Hum Mol Genet       Date:  1997-02       Impact factor: 6.150

6.  An apoptotic depletion of oligodendrocytes in the twitcher, a murine model of globoid cell leukodystrophy.

Authors:  M Taniike; I Mohri; N Eguchi; D Irikura; Y Urade; S Okada; K Suzuki
Journal:  J Neuropathol Exp Neurol       Date:  1999-06       Impact factor: 3.685

7.  Expression of the neu oncogene under the transcriptional control of the myelin basic protein gene in transgenic mice: generation of transformed glial cells.

Authors:  C Hayes; D Kelly; S Murayama; A Komiyama; K Suzuki; B Popko
Journal:  J Neurosci Res       Date:  1992-01       Impact factor: 4.164

8.  Programmed cell death induced by ceramide.

Authors:  L M Obeid; C M Linardic; L A Karolak; Y A Hannun
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

9.  Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors.

Authors:  G Ferrari; B L Anderson; R M Stephens; D R Kaplan; L A Greene
Journal:  J Biol Chem       Date:  1995-02-17       Impact factor: 5.157

10.  Globoid cell leukodystrophy: additional deficiency of psychosine galactosidase.

Authors:  T Miyatake; K Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1972-08-07       Impact factor: 3.575

View more
  7 in total

1.  Neuronal inclusions of α-synuclein contribute to the pathogenesis of Krabbe disease.

Authors:  Benjamin R Smith; Marta B Santos; Michael S Marshall; Ludovico Cantuti-Castelvetri; Aurora Lopez-Rosas; Guannan Li; Richard van Breemen; Kumiko I Claycomb; Jose I Gallea; Maria S Celej; Stephen J Crocker; Maria I Givogri; Ernesto R Bongarzone
Journal:  J Pathol       Date:  2014-02-20       Impact factor: 7.996

2.  C-6 Ceramide Induces p53 Dependent Apoptosis in Human Astrocytoma Grade4 (Glioblastoma Multiforme) Cells.

Authors:  Hirendra Nath Banerjee; Millon Blackshear; Jordan Williams; Zack Hawkins; Crystal Sawyer; Vinod Manglik; Shailendra Giri
Journal:  J Cancer Sci Ther       Date:  2012-02-01

Review 3.  Mechanisms of demyelination and neurodegeneration in globoid cell leukodystrophy.

Authors:  M Laura Feltri; Nadav I Weinstock; Jacob Favret; Narayan Dhimal; Lawrence Wrabetz; Daesung Shin
Journal:  Glia       Date:  2021-04-14       Impact factor: 7.452

4.  Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease.

Authors:  Gregory J Heller; Michael S Marshall; Yazan Issa; Jeffrey N Marshall; Duc Nguyen; Emily Rue; Koralege C Pathmasiri; Miriam S Domowicz; Richard B van Breemen; Leon M Tai; Stephanie M Cologna; Stephen J Crocker; Maria I Givogri; Mark S Sands; Ernesto R Bongarzone
Journal:  Mol Ther       Date:  2021-01-26       Impact factor: 11.454

5.  Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular Toxicity.

Authors:  Christopher J Folts; Nicole Scott-Hewitt; Christoph Pröschel; Margot Mayer-Pröschel; Mark Noble
Journal:  PLoS Biol       Date:  2016-12-15       Impact factor: 8.029

Review 6.  Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases.

Authors:  Marianna Mekhaeil; Kumlesh Kumar Dev; Melissa Jane Conroy
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

7.  Brainstem development requires galactosylceramidase and is critical for pathogenesis in a model of Krabbe disease.

Authors:  Nadav I Weinstock; Conlan Kreher; Jacob Favret; Duc Nguyen; Ernesto R Bongarzone; Lawrence Wrabetz; M Laura Feltri; Daesung Shin
Journal:  Nat Commun       Date:  2020-10-23       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.